17:00 EDT Design Therapeutics (DSGN) files $300M mixeds securities shelf
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- Cautious Optimism for Design Therapeutics: Hold Rating Amid Promising Phase 1 Results and Extended Development Timeline
- Design Therapeutics announces data from Phase 1 SAD/MAD trial of DT-168
- RBC sees Makary interview as potentially positive for biotech stocks
- Design Therapeutics appoints Chris Storgard as CMO
